An interventional study of Standard revisional RYGB and Revisional Banded RYGB in Revisional Bariatric Surgery, sponsored by General Committee of Teaching Hospitals and Institutes, Egypt. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by General Committee of Teaching Hospitals and Institutes, Egypt · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Weight Loss with a site in Egypt — 4 open to participants now, 4 under way, none of them phase 3. Weight Loss · Egypt.
Among the 11 studies in Weight Loss with a site in Egypt, this one is one of 2 that started in 2026, is one of 7 with no phase, and was the 10th registered.
1,821 studies on the registry are indexed under Weight Loss; 299 are open to participants now.
Browse Weight Loss studies →4 of the 11 studies in Weight Loss with a site in Egypt are open now. Recruiting first, the newest first:
Badr University · Sites in Egypt
Ages 36–58
Cairo University · Sites in Egypt
Ages 65–75
General Committee of Teaching Hospitals and Institutes, Egypt · Sites in Egypt
Ages 18–60 · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 200 Weight Loss studies recruiting now, 74 (37%) set no upper age limit and 109 (55%) stop at 75 or younger; 21 take children under 18; 57 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 240 is above the median of 80 across 1,567 interventional studies indexed under Weight Loss.
Median enrollment 150 across the 9 interventional studies, 660 across the 2 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 7 most frequent:
General Committee of Teaching Hospitals and Institutes, Egypt is the lead sponsor of 32 studies on the registry; 11 are open to participants now.
General Committee of Teaching Hospitals and Institutes, Egypt has 4 studies filed under Weight Loss — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Weight Loss with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Obesity remains a major global health challenge, with rising prevalence and significant metabolic, cardiovascular, and gastrointestinal comorbidities. Laparoscopic sleeve gastrectomy (LSG) has emerged as the most widely performed bariatric procedure due to its technical simplicity and satisfactory short- to mid-term results. However, a proportion of patients experience suboptimal weight loss, recurrent weight gain, or both.
In this study, patients with recurrent weight gain of maximum weight loss or suboptimal weight loss or both following sleeve gastrectomy were included.
Suboptimal weight loss is defined as total weight loss (TWL) of less than 20% of the preoperative weight and/or excess weight loss (EWL) of less than 50%, measured at least 12-18 months after the primary sleeve gastrectomy.
Recurrent weight gain after sleeve gastrectomy is defined as an increase of ≥20% of the maximum weight loss (from nadir weight) or an increase in BMI of >5, measured at least 24 months after the primary procedure.
Roux-en-Y gastric bypass (RYGB) is considered the procedure of choice for revisional bariatric surgery following failed LSG, offering both restrictive and malabsorptive mechanisms and effectively controlling reflux symptoms. Despite its success, long-term weight regain may still occur due to gradual dilation of the gastric pouch or gastrojejunal anastomosis. To mitigate this, the incorporation of a fixed ring or silastic band around the gastric pouch-known as ringed RYGB (R-RYGB)-has been introduced to maintain restriction, prevent pouch enlargement, and enhance long-term weight maintenance.
While B-RYGB has shown promise in primary bariatric procedures, evidence in the revisional setting remains limited and inconclusive. Few studies have systematically compared standard revisional RYGB and ringed revisional RYGB following sleeve gastrectomy, particularly regarding long-term outcomes such as sustained weight loss, food tolerance, quality of life, and comprehensive composite outcomes like the Bariatric Analysis and Reporting Outcome System (BAROS) score.
This prospective randomized controlled trial aims to fill this gap by providing 5-year comparative data on revisional RYGB versus ringed revisional RYGB after sleeve gastrectomy, assessing not only the efficacy in maintaining weight loss but also the broader impact on patient well-being, food tolerance, and overall quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard revisional RYGB
Procedure: Standard revisional RYGB
Revisional Banded RYGB
Procedure: Revisional Banded RYGB
* Small gastric pouch (\~30 mL). * 100-150 cm alimentary limb, 50 cm biliopancreatic limb.
* Standard RYGB as above. * Placement of a silastic ring (5.5-7.0 cm circumference) around the gastric pouch, \~2 cm above the gastrojejunal anastomosis.
Percent EWL (excess weight loss) and percent TWL (Total weight loss)
relative to both the pre-primary surgery (sleeve gastrectomy) weight and the pre-revisional surgery (RYGB or ringed RYGB) weight by kilograms.
Time frame: 1, 2, 3, 4, and 5 years postoperatively
Comorbidity resolution
T2DM (type 2 diabetes mellitus) Clinical Remission Criteria (T2DM) The American Diabetes Association (ADA) and other international experts define remission based on glycemic levels in the absence of glucose-lowering medications for at least 3 to 12 months. Complete Remission: HbA1c \< 5.7% and Fasting Plasma Glucose (FPG) \< 100 mg/dL. Partial Remission: HbA1c between 5.7% and 6.4% and FPG between 100-125 mg/dL. Improvement: A significant reduction in HbA1c (\>1%) or FPG (\>25 mg/dL), or a substantial decrease in medication dosage (e.g., stopping insulin) without meeting full remission criteria.
Time frame: 6 months, 1,2,3,4 and 5 years postoperatively
Comorbidity resolution
HTN (hypertension) Comparing pre- and postoperative results for hypertension (HTN) involves tracking clinical benchmarks that measure both blood pressure (BP) levels and the intensity of medical therapy required for control. Clinical Metrics for Comparison Blood Pressure Readings: Comparison of mean systolic and diastolic BP. Preoperative levels (typically around 140/90 mmHg) are compared against postoperative follow-up intervals. Medication Load: Tracking the total number of antihypertensive agents (AHMs). A common outcome is the likelihood of complete AHM discontinuation, which is significantly higher (around 32%) in surgical patients. Resolution vs. Improvement: Resolution: Often defined as achieving a BP \<140/90 mmHg (or \<130/80 mmHg per some AHA guidelines) while being off all medications. Improvement: Defined as a ≥30% reduction in antihypertensive medications while maintaining controlled BP.
Time frame: 6 months, 1,2,3,4 and 5 years postoperatively
Comorbidity resolution
OSA (obstructive sleep apnea) The most reliable way to compare status is through a follow-up polysomnography or home sleep test. Apnea-Hypopnea Index (AHI): This is the primary metric. It measures the number of pauses in breathing per hour of sleep. Cure/Resolution: Defined as an AHI \< 5. Improvement: Often defined as an AHI reduction of at least 50% or reaching a threshold of AHI \< 15. Oxygen Desaturation Index (ODI): Measures the number of times blood oxygen levels drop significantly per hour. Bariatric surgery typically leads to a marked decrease in this index. Mean and Nadir SpO2: Comparison of average and lowest oxygen saturation levels during sleep, which generally increase after surgery. Treatment Requirements CPAP Pressure: For patients who still require treatment, the required therapeutic pressure (measured in cmH2O or mbar) typically decreases post-operatively. Discontinuation Rate: A common comparison point is the percentage of patients who can stop using CPAP entirely.
Time frame: 6 months, 1,2,3,4 and 5 years postoperatively
Quality of Life (SF-36)
Quality of Life (QoL) scores typically show dramatic initial improvements, particularly in physical domains, followed by a stabilization or gradual decline over the long term. The Short Form-36 (SF-36) questionnaire measures eight health domains on a scale of 0 (lowest) to 100 (highest): Physical Component Summary (PCS): Includes Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), and General Health (GH). Mental Component Summary (MCS): Includes Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH). Typical Score Trends Pre-Surgery (Baseline): Patients often start with global QoL scores around 45.6 to 48.3. Physical component scores are typically significantly lower than population norms. 1 Year Post-Surgery: Global scores often peak, reaching approximately 79.7. Both PCS and MCS frequently return to or exceed general population norms (typically around 50 for summary scores) during this period.
Time frame: 1, 2, 3, 4, and 5 years postoperatively
Food tolerance (FTQ)
Food tolerance is a key measure of success after bariatric surgery, often assessed using the Food Tolerance Quality (FTQ), also known as the Suter Score or "Quality of Alimentation" questionnaire. This standardized tool quantifies how well you can ingest and digest various foods without symptoms like nausea, vomiting, or pain. The FTQ evaluates three main areas to produce a score between 1 and 27: Satisfaction: Your overall perception of your eating quality (from "excellent" to "very bad"). Food Variety: Your ability to eat 8 specific food groups (red meat, white meat, fish, vegetables, salad, rice, pasta, and bread) without difficulty. Vomiting/Regurgitation: The frequency of these symptoms (scored 0-6). Scoring Breakdown: ≥24: Good food tolerance. 20-24: Moderate food tolerance. \<20: Poor food tolerance.
Time frame: 6 months, 3 and 5 years postoperatively.
Comorbidity resolution
Dyslipidemia Comparing pre-operative to post-operative lipid profiles involves monitoring specific biochemical markers and clinical milestones at standardized intervals. 1\. Key Biochemical Markers Clinicians track four primary components to measure improvement or resolution: Triglycerides (TG): Usually show the most rapid and significant drop post-surgery. HDL ("Good") Cholesterol: Typically starts low pre-operatively and increases significantly over 12-15 months. LDL ("Bad") Cholesterol: Often decreases, though the extent of change can vary depending on the surgical procedure. TC/HDL Ratio: This ratio is a key indicator of cardiovascular risk reduction. Clinical Definition of Resolution A patient is often considered to have "resolved" dyslipidemia if they meet these post-operative criteria without the use of lipid-lowering medications: LDL: \<160 mg/dL (or specific target based on risk). Triglycerides: \<200 mg/dL. HDL: \>40 mg/dL (men) or \>50 mg/dL (women).
Time frame: 6 months, 1,2,3,4 and 5 years postoperatively
Safety outcomes: Bleeding
General perioperative complications: Bleeding: Major postoperative bleeding (mPOB) in bariatric patients is generally defined by the following metrics: Hemoglobin Drop: A decrease in hemoglobin levels of more than 2 g/dL, often within 48 hours. Clinical Intervention: A requirement for transfusion (e.g., more than or equal 2 units of red blood cells), therapeutic endoscopy, or surgical re-intervention. Clinical Symptoms: Tachycardia (more than 120 bpm), hypotension (less than 90 over 60 mmHg), dizzy spells, or the presence of bloody drainage.
Time frame: perioperative until 1 month postoperatively
Safety outcomes: Anastomotic leak
General perioperative complications: Anastomotic leak: CT Scan with Oral/IV Contrast: Considered the most reliable imaging modality, though CT can sometimes fail to show minor leaks.
Time frame: perioperative until 1 month postoperatively
Safety outcomes: Infection
General perioperative complications: Infection: Measurement and Diagnostic Metrics C-Reactive Protein (CRP): A key, non-specific blood marker used to predict postoperative infections. Studies indicate that high CRP levels on post-operative days (PODs) 3 and 5 are indicative of infectious complications, particularly in differentiating between simple, low-risk cases and those with severe infection. White Blood Cell Count (WBC): Frequently monitored alongside CRP for signs of systemic inflammation.
Time frame: perioperative until 1 month postoperatively
Safety outcomes: DVT/PE
General perioperative complications: Deep vein thrombosis/Pulmonary embolism Measurement and Diagnostic Methods: Imaging (Gold Standard): Spiral CT angiography (PE protocol) is the definitive diagnostic method for pulmonary embolism. Venous Ultrasound: Used to detect lower extremity DVT, which can be suspected if there is \>3 cm difference in circumference between legs, or symptomatic swelling. Laboratory Tests: D-dimer tests are used to detect fibrin degradation, helping to rule out thrombosis.
Time frame: perioperative until 1 month postoperatively
Safety outcomes: Ring-related complications
Ring-related complications: Early: leak, hemorrhage, melena, vomiting, internal or port-site hernia. Late: slippage, erosion, stenosis, chronic vomiting, persistent food intolerance.
Time frame: At 1, 3, 4, and 5 years, or earlier if symptomatic (dysphagia, vomiting, suspected stricture, ulcer, or band-related complication).
Reoperation rates
The reoperation rates done in a number of patients between the 2 groups.
Time frame: 1, 2, 3, 4, and 5 years postoperatively
Operative data
operative time between the 2 groups (RYGB vs. B-RYGB)
Time frame: Intraoperative
Metabolic/hormonal panel
Clinical Significance Appetite Suppression: Elevated PYY promotes an early sense of satiety and reduced meal size, contributing to sustained weight loss. Diabetes Remission: PYY is a key humoral factor in the early recovery of impaired insulin and glucagon secretion after surgery, often independent of weight loss. Predicting Outcomes: The ability of PYY to increase early after surgery (measured 6 months post-op) is a strong predictor of long-term weight maintenance at 3 years. Common PYY Measurement Values Healthy circulating levels vary based on fasting state and sex: Fasting Levels: Typically range from 10 to 17 pmol/L in lean individuals. In mass units, average fasting levels are often around 100-120 pg/mL. Postprandial (After Meal) Peak: Levels usually rise within 1 hour of eating, typically reaching 23-45 pg/mL or higher depending on meal size and caloric density.
Time frame: 6months, 1,2,3 and 5 years postoperatively
Metabolic/hormonal panel
Measuring endogenous GLP-1 is challenging because it has a very short half-life of roughly 1-2 minutes before being degraded by enzymes. Fasting Levels: Typically range from 0 to 15 pmol/L. Post-Meal Levels: Can increase 2- to 3-fold following food consumption. Measurement Methods: Laboratory tests primarily use ELISA (Enzyme-Linked Immunosorbent Assay) to detect either "active" GLP-1 or "total" GLP-1. One of the primary reasons bariatric surgery is so effective for weight loss and type 2 diabetes remission is the dramatic natural increase in GLP-1 production after surgery. Postprandial (After-Meal) Levels: Following procedures like Roux-en-Y gastric bypass (RYGB), post-meal GLP-1 levels can increase by as much as 10-fold compared to pre-surgery levels. This happens because food reaches the distal part of the small intestine much faster than before. Weight Loss Marker: Higher post-surgical GLP-1 responses are often associated with more robust and sustained weight loss.
Time frame: 6months, 1,2,3 and 5 years postoperatively
Metabolic/hormonal panel
GIP (Gastric Inhibitory Polypeptide or Glucose-dependent Insulinotropic Polypeptide) measurements involve determining blood levels of this hormone, primarily for researching metabolism, obesity, and diabetes. Total GIP (active 1-42 + inactive 3-42) is measured using ELISA kits. RYGB typically leads to a decrease in GIP levels, particularly in response to food (postprandial). Mechanism: The "Foregut Hypothesis" suggests that bypassing the duodenum and proximal jejunum-where GIP-producing K-cells are most concentrated-prevents nutrients from stimulating these cells. Fasting Levels: Many studies show a significant decrease in fasting GIP levels within 1 to 6 months post-surgery. Postprandial Levels: Research consistently finds lower post-meal GIP concentrations compared to pre-operative levels. Clinical Impact: Lower GIP is associated with reduced fat accumulation and improved insulin sensitivity, contributing to the resolution of Type 2 Diabetes.
Time frame: 6months, 1,2,3 and 5 years postoperatively
Metabolic/hormonal panel
Leptin Bariatric surgery leads to significant decreases in fasting leptin levels, often reported as a decline from pre-operative obesity levels. Leptin is typically measured through blood tests using the following laboratory techniques: ELISA (Enzyme-Linked Immunosorbent Assay): The most common method used in clinical research to quantify serum or plasma leptin concentrations. Normal Ranges (Reference): Females: 0.5 to 15.2 ng/mL. Males: 0.5 to 12.5 ng/mL.
Time frame: 1,3 and 5 years postoperatively
Metabolic/hormonal panel
Ghrelin Measurement results are more heterogeneous. While some studies show a significant decrease in the first few months, others report that levels may return to or even exceed baseline at one year. Researchers and clinicians use several specialized techniques to measure ghrelin in bariatric patients: Assay Types: ELISA (Enzyme-Linked Immunosorbent Assay): The most common method for measuring total or acylated ghrelin in blood plasma or serum. Before surgery, ghrelin levels in obese individuals are typically lower than in lean individuals. Obese Baseline: Often ranges between 300-600 pg/mL for total ghrelin. Lean Reference: Generally higher, often exceeding 800 pg/mL.
Time frame: 1,3 and 5 years postoperatively
Plan to share: Yes
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2031, 60 months after the start.
Of 671 non-industry interventional studies with no phase under Weight Loss, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 60 months is above that.
Counting every sponsor, half of 730 studies reached it within 24 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
General Committee of Teaching Hospitals and Institutes, Egypt